$31.095
+1.894 (+6.09%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
該買進 IRulya Therapeutics Inc. 股票嗎？
IRulya Therapeutics Inc is not a good buy right now due to its significant financial losses and weak performance indicators. The stock is currently priced at 31.09, but it has a forward P/E of 0 and a negative EPS estimate of -0.8300 for the upcoming earnings report. Additionally, the company has reported a net income loss of -39,458,000 for Q4 2025, indicating ongoing financial struggles. The main risk is its declining current ratio, which has fallen to 0.53, suggesting potential liquidity issues.
IRLA 股價於 Friday 收在 $31.09，此前上漲 +6.09%
IRulya Therapeutics Inc. (IRLA) last closed at $31.0949993, gaining +6.09%. These facts feed the 1-day and 1-week IRLA price prediction above.
預測驅動因素
IRulya Therapeutics Inc.（IRLA）的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Seasonality
Bearish
IRLA 季節性分析
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。